A Bolt driver was killed in Pretoria West after being attacked by two passengers. Dashcam footage shows the violent struggle, sparking outrage on social media.

Amazing what can happen in a few months with enough motivation. Like, magically finding an extra seven miles of EPA-estimated range. Late on Friday, General Motors announced the 2027 Chevrolet Bolt is ...

South Africa has emerged as Bolt’s leading market for dash cam adoption, with over 2,724 drivers installing the ride-hailing company’s approved cameras. This places the country well ahead of all other ...

We have two orbbec cameras connected on the same workstation: one astra2 and one femto bolt. We are using ROS 2 humble distro when using the cameras. The problem we have is that executing the file ...

I got behind the wheel of the 2027 Chevrolet Bolt to see how Chevy’s latest electric hatchback drives—here’s what stood out most. At a press event hosted by Chevrolet at Universal Studios Hollywood, I ...

Earlier this morning, some of the first details of the new 2027 Chevrolet Bolt percolated out onto the internet thanks to some people that attended a special preview for existing owners last night in ...

GM is bringing back its Chevrolet Bolt with a new model that it expects to account for much of its electric-vehicle volume next year. The company said Thursday its 2027 Chevrolet Bolt will begin ...

General Motors has heavily upgraded the Bolt, with more range and faster charging speeds. It won't be on sale for an extended time period, the automaker said in a media briefing on Thursday. Recently, ...

The new Bolt will start under $30,000, which should make it a welcome addition to the stubbornly expensive EV market in the US. The new Bolt will start under $30,000, which should make it a welcome ...

The starting price for the Bolt's LT comfort package is $29,990. It’s unclear how impactful losing the EV tax credits will be for Bolt sales. The Chevrolet Bolt is back ― for now. General Motors said ...

Bolt Biotherapeutics has halved its workforce for the second time in two years as the oncology biotech delays a readout of its lead immunotherapy. The company had previously been expecting initial ...